Problem: Poor translation from animal studies to clinical success
Poor predictive value from animal respiratory studies wastes time and money and delays patient benefit. Many teams seek a reliable respiratory CRO because expertise in model selection, dosing and endpoints matters more than fancy equipment. The problem is not lack of tools; it is mismatch between the question and the experimental design.

Why common respiratory models fail — and what experience shows
Experience tells a clear story: models fail when endpoints are surrogate, exposure is unrealistic, or adaptive responses are ignored. Expert labs and peer-reviewed groups that present at major forums such as the American Thoracic Society (ATS) International Conference have repeatedly highlighted issues with protocol variability. Practical work with established murine allergic-challenge setups has clarified which readouts track with human disease. For projects that need that alignment, validated approaches like the asthma mouse model are the right starting point, used alongside respiratory physiology and histology to reduce guesswork.
Alternatives and how to weigh them
Pick models by the question you must answer. If airway hyperreactivity is critical, choose whole-animal bronchoconstriction readouts. If inflammatory signalling is central, immunophenotyping and cytokine panels matter more. Consider ex vivo human tissue or organotypic cultures when human-specific receptors or metabolism drive response. Use in silico exposure modelling to set realistic dosing. Each choice trades biological realism against cost and throughput; document that trade-off and keep the decision defensible.

Common pitfalls teams should avoid
Do not borrow protocols blindly. Single time-point measures often miss disease dynamics. Over-reliance on high drug doses produces off-target toxicity that masks mechanism. Small cohort sizes reduce reproducibility but inflate effect sizes. Neglecting blinding and randomisation invites bias. The remedy is simple: define primary endpoints before studies start, power studies to those endpoints, and include internal replication clauses in the protocol.
How a partner reduces project risk
Choose partners who map study aims to appropriate models, not the other way around. Seek teams that publish methods, run cross-validation exercises, and provide transparent raw data. That combination—clear aims, matched models, reproducible methods—makes findings interpretable and actionable for next-stage decisions. For groups that need such an approach, KCI Biotech integrates model selection, validated respiratory endpoints and quality controls so scientific questions are tested with the right tools rather than hoped-for ones.
